# Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

> **NCT04729296** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)**

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Golimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04729296
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to COVID-19 related clinical limitations
- **Last updated:** 2021-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729296, "Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04729296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*